Regarding adults, the therapeuticarsenal proposed in the CGTP1 includes angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptorblockers (ARBs), aldosterone antagonists, sodium-glucose cotransporter 2 inhibitors(SGLT2 inhibitors), and the conservative management of anemia, mineral and bonedisorder, SAH, acidemia, and cardiovascular disease. This evidence concerns the gene SLC5A2 and anemia (phenotype).